Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00813111 · ClinicalTrials.gov registry record · Phase 3

Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation

A Phase 3 study, sponsored by Pacira Pharmaceuticals.

Terminated
Registry status
Phase 3
Development phase
136
Enrollment target

NCT00813111: Clinical Trial Phase 3 study, sponsored by Pacira Pharmaceuticals.

NCT00813111 is a Phase 3 study that was terminated before completion, run by Pacira Pharmaceuticals. The registered enrollment target is 136 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00813111, a Phase 3 study, was terminated before completion, sponsored by Pacira Pharmaceuticals.

TERMINATED
Registry status
Phase 3
Development phase
136 participants
Enrollment target

Study Summary

The purpose of this study is to provide a more effective postoperative method of pain control for patients undergoing cosmetic sub-muscular breast augmentation. Appropriate postoperative pain management contributes to faster patient mobilization, shortened hospital stays, and reduced healthcare costs.

Primary Outcome

Assessments of postoperative pain included pain intensity at rest (using the NRS at rest \[NRS-R\] and with activity \[using the NRS-A\]) where the prescribed activity was raising both arms. Pain intensity was assessed on a scale of 0 to 10, where 0=no pain and 10=worst possible pain.

Interventions

  • DRUG Bupivacaine HCl
  • DRUG SKY0402

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2008-11
Est. Completion 2009-02
Phase Phase 3
Pacira Pharmaceuticals

88 total trials

Why NCT00813111 stopped before completion

NCT00813111 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).

The record links to 0 conditions, and to 2 interventions - of which Bupivacaine HCl is the first listed.

NCT00813111 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00813111 about?

NCT00813111 is a clinical study titled "Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation". The purpose of this study is to provide a more effective postoperative method of pain control for patients undergoing cosmetic sub-muscular breast augmentation. Appropriate postoperative pain management contributes to faster patient mobilization, shortened hospital stays, and reduced healthcare cost...

What is the current status of trial NCT00813111?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2008-11. Estimated completion is 2009-02.

What interventions are being tested in trial NCT00813111?

The interventions under investigation include: Bupivacaine HCl (DRUG), SKY0402 (DRUG).

Who is sponsoring clinical trial NCT00813111?

This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00813111's enrollment target sits among peer trials

136 1580th of 2000 higher than 419 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01555892 · 136 participants · Phase 1

    Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

  • NCT03216525 · 136 participants · Phase 3

    Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

  • NCT04476901 · 136 participants · Phase 2

    Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

  • NCT04603898 · 136 participants · NA

    Oxalate Formation From Ascorbic Acid

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00813111, the US trial registry maintained by the National Library of Medicine. NCT00813111 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.